ACLARION NEW DL-,00001 Aktie Logo
US6551872012

ACLARION NEW DL-,00001 Aktie

Ins Portfolio
60% Chancen, 40% Gelassenheit. Aktien und Anleihen in einem LifeStrategy ETF. Jetzt entdecken
Anzeige

Kurse werden geladen...

Prognose

Kaufen
  1
Halten
  1
Verkaufen
  0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News


  • Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

    USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologies CLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 20, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of Keck Medical Center of USC as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial site.» Mehr auf globenewswire.com


  • Aclarion Announces Texas Back Institute as New CLARITY Trial Site

    Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of the Texas Back Institute (TBI) as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial site.» Mehr auf globenewswire.com


  • Aclarion Welcomes Advocate Health as CLARITY Trial Site

    Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of Advocate Aurora Research Institute, part of Advocate Health, as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) site.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte ACLARION NEW DL-,00001 Aktie einen Umsatz von +17,55k und ein Nettoeinkommen von 1,88 Mio
(EUR)März 2025
YOY
Umsatz+17,55k87,32%
Bruttoeinkommen4,15k91,78%
Nettoeinkommen1,88 Mio15,28%
EBITDA1,38 Mio26,25%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+3,75 Mio
Anzahl Aktien
582,37k
52 Wochen-Hoch/Tief
+3.023,94 - +5,36
DividendenNein
Beta
1,21
KGV (PE Ratio)
2,47
KGWV (PEG Ratio)
+0,05
KBV (PB Ratio)
+1,04
KUV (PS Ratio)
+79,51

Unternehmensprofil

Aclarion, Inc. ist ein Technologieunternehmen im Gesundheitswesen, das in den Vereinigten Staaten Softwareanwendungen für die Magnetresonanzspektroskopie (MRS) entwickelt. Es bietet die NOCISCAN-LS Post-Processor-Suite an, die NOCICALC-LS umfasst, das die erfassten Bandscheiben-MRS-Daten empfängt und verarbeitet, um die Werte degenerativer Schmerz-Biomarker zu berechnen, sowie NOCIGRAM-LS, eine Software zur Unterstützung klinischer Entscheidungen. Das Unternehmen war früher als Nocimed, Inc. bekannt und änderte im Dezember 2021 seinen Namen in Aclarion, Inc. Aclarion, Inc. wurde im Jahr 2008 gegründet und hat seinen Sitz in San Mateo, Kalifornien.

Name
ACLARION NEW DL-,00001 Aktie
CEO
Brent Ness
SitzBroomfield, ca
USA
Website
Industrie
Gesundheitswesen: Ausstattung und Produkte
Börsengang
Mitarbeiter5

Ticker Symbole

BörseSymbol
NASDAQ
ACON
🍪

Parqet nutzt Cookies.Erfahre Mehr